Tax Cuts Enable Access To Key Drugs, But Govt. Budget Fails To Boost Research, India's Drug Industry Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Long-term renewal of the 150 percent weighted tax credit for in-house R&D, grant support for basic research needed to encourage growth, drug companies assert.